Arcadia Biosciences, Inc. (RKDA) intrinsic value & 10-year financials
Arcadia Biosciences, Inc. (RKDA) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 4.8% a year to $4.9M, with an average return on invested capital of 823.8%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.17
- Market cap
- $225.7K
- Revenue (FY2025)
- $4.9M
- Revenue growth (10-yr CAGR)
- 4.8%
- ROIC (10-yr avg)
- 823.8%
- Free cash flow (FY2025)
- —
RKDA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $4.9M | -$2.3M | -$1.71 | — | -51.5% | — |
| FY2024 | $5.0M | -$7.0M | -$5.17 | -$9.6M | -72.3% | -86.3% |
| FY2023 | $5.3M | -$14.0M | -$11.29 | -$15.3M | -261.5% | -354.0% |
| FY2022 | $10.0M | -$15.4M | -$12.82 | -$14.0M | -189.0% | -624.7% |
| FY2021 | $6.8M | -$14.7M | -$13.78 | -$26.9M | -524.0% | -275.3% |
| FY2020 | $8.0M | -$4.7M | — | -$32.6M | -159.0% | -112.7% |
| FY2019 | $1.2M | -$28.8M | — | -$18.7M | -1657.9% | -2236.7% |
| FY2018 | $1.5M | -$13.5M | — | -$13.9M | -1152.3% | 11209.3% |
| FY2017 | $4.0M | -$15.7M | — | -$14.0M | -355.6% | -64.8% |
| FY2016 | $3.2M | -$19.6M | — | -$17.3M | -584.1% | -41.1% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Arcadia Biosciences, Inc. has demonstrated mature, steady growth, with revenue compounding at 4.8% annually over the past decade.
Arcadia Biosciences, Inc. has historically struggled to out-earn its cost of capital, averaging just -25.3% ROIC.
Arcadia Biosciences, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Arcadia Biosciences, Inc. is modeled at 4.8% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-26.67 per share.